Sustained release of injectable zinc-recombinant hirudin suspensions: Development and validation of in vitro release model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 45, Issue 3, 1998, Pages 259-264

  Gietz, Ursula ^a   Arvinte, Tudor ^b   Mader, Evelyn ^b   Oroszlan, Peter ^b   Merkle, Hans P ^a  

^a ETH ZURICH   (Switzerland)

^b CIBA GEIGY LTD   (Switzerland)

Author keywords

In vitro release model; Insulin; Recombinant hirudin; Statistical moment analysis; Sustained biological activity

Indexed keywords

HIRUDIN; INSULIN; INSULIN ZINC SUSPENSION; LEPIRUDIN; LEPIRUDIN ZINC SUSPENSION; NEUTRAL INSULIN; UNCLASSIFIED DRUG;

ARTICLE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG RELEASE; DRUG SCREENING; SUSTAINED RELEASE PREPARATION; VALIDATION PROCESS;

ALGORITHMS; ANTICOAGULANTS; BUFFERS; DELAYED-ACTION PREPARATIONS; FIBER OPTICS; HIRUDINS; HUMANS; INSULIN; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; SUSPENSIONS;

EID: 0032077523     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(98)00008-3     Document Type: Article

References (14)

1. [1] S.R. Stone, J. Hofsteenge, Kinetics of the inhibition of thrombin by hirudin, Biochemistry 25 (1986) 4622-4628.
2. [2] E. Deutsch, A. Koneti Rao, R.W. Colman, Selective thrombin inhibitors: next generation of anticoagulants, J. Am. Coll. Cardiol. 22 (4) (1993) 1089-1092.
3. [3] T. Arvinte, Pharmaceutical compositions containing hirudin. Eur. Patent 0624375A2 (1994).
4. [4] U. Gietz, T. Arvinte, H.P. Merkle, Preformulation aspects of hirudin: pH dependent co-precipitation of hirudin and zinc, in: Proc. 1st World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Budapest, Hungary, 1995, pp. 54-55.
5. [5] D.T. Graham, A.R. Pomeroy, An in vitro test for the duration of action of insulin suspensions, J. Pharm. Pharmacol. 36 (1984) 427-430.
6. [6] R. Peschka, Herstellung und Entwicklung liposomenhaltiger Zubereitungen mit hydrophilen Arzneistoffen zur topischen Anwendung, Ph.D. Thesis, University of Tübingen, Germany, 1994.
7. [7] B.J. Spargo, R.O. Cliff, F.M. Rollwagen, A.S. Rudolph, Controlled release of transforming growth factor-(from lipid-based microcylinders, J. Microencapsulation 12 (3) (1995) 247-254.
8. [8] P. Oroszlan, Ch. Thommen, M. Wehrli, G. Duveneck, M. Ehrat, Automated optical sensing system for biochemical assays: A challenge for ELISA?, Anal. Methods Instrum. 1 (1) (1993) 43-51.
9. [9] J. Brange, Stability of Insulin. Studies on the Physical and Chemical Stability of Insulin in Pharmaceutical Formulation, Kluwer, London, 1994, pp. 18-23.
10. [10] M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72 (1976) 248-254.
11. [11] J.M. Schlaeppi, S. Vekemans, H. Rink, J.Y. Chang, Preparation of monoclonal antibodies to hirudin and hirudin peptides, Eur. J. Biochem. 188 (1990) 463-470.
12. [12] D. Gygax, L. Botta, P. Graf, C. Pfister, G. Lefevre, P. Oroszlan, M. Ehrat, Immunoassays in monitoring biotechnological drugs, Ther. Drug Monit. 18 (4) (1996) 405-409.
13. [13] D. Brockmeier, In vitro/In vivo correlation of dissolution using moments of dissolution and transit times, Acta Pharm. Technol. 32 (4) (1986) 164-174.
14. [14] G. Löffler, P.E. Petrides, Physiologische Chemie, 4th ed., Springer, Berlin, 1988, p. 546.